journal article·2025-05Open access

SERPINE1 Facilitates Metastasis in Gastric Cancer Through Anoikis Resistance and Tumor Microenvironment Remodeling

Bofang Wang, Baohong Gu, Lei Gao, Chenhui Ma, Xuemei Li, Yunpeng Wang, Jike Hu, Na Wang, Lin Xiang, Yang Yu, Junge Deng, Xueyan Wang, Puyi He, Dan Zou, Pengxian Tao, Yanling Ma, Kewei Song, Zhijian Han, Tao Zhang, Hao Chen

Small· Volume 21· Issue 19

Abstract

Abstract SERPINE1 is a serine protease inhibitor upregulated in various malignancies and pivotal in gastric cancer (GC) metastasis and the tumor microenvironment (TME). This study elucidates the mechanisms by which SERPINE1 mediates anoikis resistance and fosters an immunosuppressive TME in advanced GC. SERPINE1 is highly expressed in GC tissues and metastatic lesions and serves as an independent risk factor for poor prognosis. The transcriptional activation of SERPINE1 by CEBPB triggers the PI3K/AKT and EMT signaling pathway via autocrine mechanisms, enhancing anoikis resistance and metastatic potential in GC cells. Furthermore, SERPINE1 facilitates M2 macrophage polarization by binding to lipoprotein receptor‐related protein 1 (LRP1) in a paracrine manner, suppressing CD8+ T‐cell infiltration and functionality in the TME. Therapeutic intervention combining SERPINE1 inhibition with PD‐1 blockade exhibits synergistic antitumor effects. Clinically, high SERPINE1 expression is associated with an increased risk of recurrence following immune checkpoint inhibitor therapy in patients with advanced GC. These findings suggest that SERPINE1 is a critical driver of GC progression through anoikis resistance and TME remodeling. Hence, SERPINE1 can offer a promising therapeutic target and represent a predictive biomarker for immunotherapy outcomes in GC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Cancer Mechanisms and Therapy · Galectins and Cancer Biology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Second Hospital & Clinical Medical School Lanzhou University Lanzhou China

Department of Surgical Oncology The Second Hospital & Clinical Medical School Lanzhou University Lanzhou China

Gansu Provincial Key Laboratory of Environmental Oncology The Second Hospital & Clinical Medical School Lanzhou University Lanzhou China

Department of Pathology The Second Hospital & Clinical Medical School Lanzhou University Lanzhou China

Department of Thyroid Surgery Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou China

Cadre Ward of General Surgery Department Gansu Provincial Hospital Lanzhou China

Department of Oncology The First Hospital of Lanzhou University Lanzhou China

The Key Laboratory of Humanized Animal Models The Second Hospital & Clinical Medical School Lanzhou University Lanzhou China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Gansu Province

References (64)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1016/S2468-1253(19)30342-510.1016/S2468-1253(19)30342-5 ↗
3. 10.1038/s41591-018-0101-z10.1038/s41591-018-0101-z ↗
4. 10.1186/s12943-024-01945-910.1186/s12943-024-01945-9 ↗
5. 10.1158/0008-5472.CAN-19-074310.1158/0008-5472.CAN-19-0743 ↗
6. 10.1016/j.trsl.2022.08.01010.1016/j.trsl.2022.08.010 ↗
7. 10.1038/ng.298310.1038/ng.2983 ↗
8. 10.1016/j.trecan.2021.12.00810.1016/j.trecan.2021.12.008 ↗
9. 10.7150/ijbs.6993310.7150/ijbs.69933 ↗
10. 10.3389/fgene.2022.95765510.3389/fgene.2022.957655 ↗
11. 10.1160/TH05-01-003310.1160/TH05-01-0033 ↗
12. 10.1111/jop.1272110.1111/jop.12721 ↗
13. 10.3748/wjg.v20.i18.553310.3748/wjg.v20.i18.5533 ↗
14. 10.1155/2017/650496010.1155/2017/6504960 ↗
15. 10.1158/1541-7786.MCR-05-025710.1158/1541-7786.MCR-05-0257 ↗
16. 10.1111/cas.1214310.1111/cas.12143 ↗
17. 10.1158/0008-5472.CAN-06-462910.1158/0008-5472.CAN-06-4629 ↗
18. 10.1371/journal.pone.010604910.1371/journal.pone.0106049 ↗
19. 10.1155/2022/264782510.1155/2022/2647825 ↗
20. 10.1016/j.jid.2021.03.03010.1016/j.jid.2021.03.030 ↗
21. 10.3389/fimmu.2024.136589410.3389/fimmu.2024.1365894 ↗
22. Rossi Sebastiano M. · Sci. Adv. · 2020 · 6
23. 10.1038/s41419-018-0808-210.1038/s41419-018-0808-2 ↗
24. 10.3892/ijo.2021.523910.3892/ijo.2021.5239 ↗
25. 10.1016/j.canlet.2023.21611710.1016/j.canlet.2023.216117 ↗
26. 10.1016/j.bbrc.2014.07.07010.1016/j.bbrc.2014.07.070 ↗
27. 10.1016/j.celrep.2018.10.08210.1016/j.celrep.2018.10.082 ↗
28. 10.1016/j.modpat.2023.10025610.1016/j.modpat.2023.100256 ↗
29. 10.1038/s41423-020-00570-y10.1038/s41423-020-00570-y ↗
30. 10.1073/pnas.82.24.871010.1073/pnas.82.24.8710 ↗
31. 10.1182/blood.V69.2.381.38110.1182/blood.V69.2.381.381 ↗
32. 10.1586/erm.11.4710.1586/erm.11.47 ↗
33. 10.1093/jnci/94.2.11610.1093/jnci/94.2.116 ↗
34. 10.1038/bjc.1998.15410.1038/bjc.1998.154 ↗
35. Niki M. · Lung Cancer · 2017 · 8 · 91
36. 10.1016/j.ejca.2013.01.00710.1016/j.ejca.2013.01.007 ↗
37. 10.1007/s00432-011-1126-610.1007/s00432-011-1126-6 ↗
38. Robert C. · Clin. Cancer Res. · 1999 · 5 · 2094
39. 10.1002/(SICI)1097-0215(19981023)79:5<449::AID-IJC1>3.0.CO;2-010.1002/(SICI)1097-0215(19981023)79:5<449::AID-IJC1>3.0.CO;2-0 ↗
40. 10.1007/s10555-019-09806-410.1007/s10555-019-09806-4 ↗
41. 10.1016/0014-5793(86)81113-910.1016/0014-5793(86)81113-9 ↗
42. 10.1055/s-2007-100262010.1055/s-2007-1002620 ↗
43. 10.1155/2020/547927910.1155/2020/5479279 ↗
44. 10.1111/j.1349-7006.2003.tb01350.x10.1111/j.1349-7006.2003.tb01350.x ↗
45. Sakakibara T. · Hepatogastroenterology · 2008 · 55 · 1480
46. 10.1007/s10620-020-06691-810.1007/s10620-020-06691-8 ↗
47. 10.1002/1878-0261.1291110.1002/1878-0261.12911 ↗
48. 10.1038/s41388-021-01988-y10.1038/s41388-021-01988-y ↗
49. 10.1038/s41419-022-04890-x10.1038/s41419-022-04890-x ↗
50. 10.1038/s41416-022-01747-010.1038/s41416-022-01747-0 ↗
51. 10.7150/jca.10602910.7150/jca.106029 ↗
52. 10.7717/peerj.709110.7717/peerj.7091 ↗
53. 10.3389/fonc.2021.79838510.3389/fonc.2021.798385 ↗
54. 10.1016/j.bbadis.2023.16666510.1016/j.bbadis.2023.166665 ↗
55. 10.1038/s41420-024-01886-810.1038/s41420-024-01886-8 ↗
56. 10.1016/j.bbrc.2020.04.16010.1016/j.bbrc.2020.04.160 ↗
57. 10.1038/s41598-021-94360-910.1038/s41598-021-94360-9 ↗
58. 10.1016/j.canlet.2024.21680710.1016/j.canlet.2024.216807 ↗
59. Takahashi N. · Cancer Med. · 2023 · 12
60. T.Masuda T.Hirata T.Sakamoto Y.Tsubata E.Ichihara T.Kozuki H.Shoda M.Motonaga T.Yoshida M.Fukutani K.Tsuji‐Takayama A.Tamura H.Amagase H.Fujihara G.Aoki T.Akita Y.Orihashi T.Miyata N.Hattori J.Thorac Dis 2024 16 3381.10.21037/jtd-23-1858 ↗
61. 10.1093/bjd/ljae23110.1093/bjd/ljae231 ↗
62. 10.1016/j.apsb.2022.12.01210.1016/j.apsb.2022.12.012 ↗
63. 10.1038/jcbfm.2009.27210.1038/jcbfm.2009.272 ↗
64. 10.1371/journal.pone.013378610.1371/journal.pone.0133786 ↗